Rituximab's cost for the treatment of primary cold agglutinin disease should not limit its use

Haematologica. 2006 Mar;91(3):ECR05.
No abstract available

MeSH terms

  • Anemia, Hemolytic, Autoimmune / drug therapy*
  • Anemia, Hemolytic, Autoimmune / economics*
  • Antibodies, Monoclonal / economics*
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Murine-Derived
  • Cost-Benefit Analysis
  • Humans
  • Rituximab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab